Anaplastic large cell lymphoma: One or more entities among T-cell lymphoma?

Hematological Oncology

Volumn 27, Issue 4, 2009, Pages 161-170

  Fornari, Alessandro ^a   Piva, Roberto ^a,b   Chiarle, Roberto ^a   Novero, Domenico ^a   Inghirami, Giorgio ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ALCL; ALK; T cell lymphoma

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CD30 ANTIGEN; CLATHRIN HEAVY CHAIN; CLATHRIN HEAVY CHAIN LIKE 1; CONTRACTILE PROTEIN; NUCLEOPHOSMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN SH2; PROTEIN TPM3; PROTEIN TPM4; STAT PROTEIN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; PROTEIN TYROSINE KINASE;

CANCER CLASSIFICATION; CHROMOSOME 2; CHROMOSOME 5; CHROMOSOME TRANSLOCATION 2; GENE EXPRESSION PROFILING; GENETIC HETEROGENEITY; GENETICS; HISTOPATHOLOGY; HUMAN; HYBRIDIZATION; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LEUKEMOGENESIS; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; SYMPTOMATOLOGY; T CELL LYMPHOMA; ENZYMOLOGY; PATHOLOGY;

HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; LYMPHOMA, T-CELL, PERIPHERAL; PROTEIN-TYROSINE KINASES;

EID: 73349134698     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.897     Document Type: Review

References (82)

1. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985; 66(4): 848-858.
2. Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification: Tumours of Hematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2008.
3. Savage KJ, Peripheral T-cell lymphomas. Blood Rev 2007; 21(4): 201-216.
4. Wellmann A, Otsuki T, Vogelbruch M, Clark HM, Jaffe ES, Raffeld M. Analysis of the t(2;5)(p23;q35) translocation by reverse transcription- polymerase chain reaction in CD30+ anaplastic large-cell lymphomas, in other non-Hodgkin's lymphomas of T-cell phenotype, and in Hodgkin's disease. Blood 1995; 86(6): 2321-2328.
5. Ladanyi M, Cavalchire G, Morris SW, Downing J, Filippa DA. Reverse transcriptase polymerase chain reaction for the Ki-1 anaplastic large cell lymphoma-associated t(2;5) translocation in Hodgkin's disease. Am J Pathol 1994; 145(6): 1296-1300.
6. Elmberger PG, Lozano MD, Weisenburger DD, Sanger W, Chan WC. Transcripts of the npm-alk fusion gene in anaplastic large cell lymphoma, Hodgkin's disease, and reactive lymphoid lesions. Blood 1995; 86(9): 3517-3521.
7. Stansfeld AG, Diebold J, Noel H, et al. Updated Kiel classification for lymphomas. Lancet 1988; 1(8580): 292-293.
8. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84(5): 1361-1392.
9. Fischer P, Nacheva E, Mason DY, et al. A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene. Blood 1988; 72(1): 234-240.
10. Benz-Lemoine E, Brizard A, Huret JL, et al. Malignant histiocytosis: a specific t(2;5)(p23;q35) translocation? Review of the literature. Blood 1988; 72(3): 1045-1047.
11. Mason DY, Bastard C, Rimokh R, et al. CD30-positive large cell lymphomas ('Ki-1 lymphoma') are associated with a chromosomal translocation involving 5q35. Br J Haematol 1990; 74(2): 161-168.
12. Rimokh R, Magaud JP, Berger F, et al. A translocation involving a specific breakpoint (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma ('Ki-1 lymphoma). Br J Haematol 1989; 71(1): 31-36.
13. Kaneko Y, Frizzera G, Edamura S, et al. A novel translocation, t(2;5)(p23;q35), in childhood phagocytic large T-cell lymphoma mimicking malignant histiocytosis. Blood 1989; 73(3): 806-813.
14. Bitter MA, Franklin WA, Larson RA, et al. Morphology in Ki-1(CD30)-positive non-Hodgkin's lymphoma is correlated with clinical features and the presence of a unique chromosomal abnormality, t(2;5)(p23;q35). Am J Surg Pathol 1990; 14(4): 305-316.
15. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263(5151): 1281-1284.
16. Shiota M, Fujimoto J, Takenaga M, et al. Diagnosis of t(2;5)(p23;q35)-associated Ki-1 lymphoma with immunohistochemistry. Blood 1994; 84(11): 3648-3652.
17. Pulford K, Lamant L, Morris SW, et al. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 1997; 89(4): 1394-1404.
18. Shiota M, Nakamura S, Ichinohasama R, et al. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. Blood 1995; 86(5): 1954-1960.
19. Falini B, Pileri S, Zinzani PL, et al. ALK+ lymphoma: clinicopathological findings and outcome. Blood 1999; 93(8): 2697-2706.
20. Stein H, Foss HD, Dürkop H, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000; 96(12): 3681-3695.
21. Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008; 111(12): 5496-5504.
22. Fraga M, Brousset P, Schlaifer D, et al. Bone marrow involvement in anaplastic large cell lymphoma. Immunohistochemical detection of minimal disease and its prognostic significance. Am J Clin Pathol 1995; 103(1): 82-89.
23. Ten Berge RL, De Bruin PC, Oudejans JJ, Ossenkoppele GJ, Van der Valk P, Meijer CJ., ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. Histopathology 2003; 43(5): 462-469.
24. Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999; 93(11): 3913-3921.
25. Falini B, Pulford K, Pucciarini A, et al. Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. Blood 1999; 94(10): 3509-3515.
26. Benharroch D, Meguerian-Bedoyan Z, Lamant L, et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood 1998; 91(6): 2076-2084.
27. Jaffe ES. Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology. Mod Pathol 2001; 14(3): 219-228.
28. Kinney MC, Collins RD, Greer JP, Whitlock JA, Sioutos N, Kadin ME. A small-cell-predominant variant of primary Ki-1 (CD30)+ T-cell lymphoma. Am J Surg Pathol 1993; 17(9): 859-868.
29. Pittaluga S, Wlodarska I, Pulford K, et al. The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements. Am J Pathol 1997; 151(2): 343-351.
30. Pileri S, Falini B, Delsol G, et al. Lymphohistiocytic T-cell lymphoma (anaplastic large cell lymphoma CD30+/Ki-1 + with with a high content of reactive histiocytes). Histopathology 1990; 16(4): 383-391.
31. Pileri SA, Pulford K, Mori S, et al. Frequent expression of the NPM-ALK chimeric fusion protein in anaplastic large-cell lymphoma, lympho-histiocytic type. Am J Pathol 1997; 150(4): 1207-1211.
32. Chott A, Kaserer K, Augustin I, et al. Ki-1-positive large cell lymphoma. A clinicopathologic study of 41 cases. Am J Surg Pathol 1990; 14(5): 439-448.
33. Kadin ME. Anaplastic large cell lymphoma and its morphological variants. Cancer Surv 1997; 30: 77-86.
34. Chan JK, Buchanan R, Fletcher CD. Sarcomatoid variant of anaplastic large-cell Ki-1 lymphoma. Am J Surg Pathol 1990; 14(10): 983-988.
35. Frizzera G. The distinction of Hodgkin's disease from anaplastic large cell lymphoma. Semin Diagn Pathol 1992; 9(4): 291-296.
36. Chittal SM, Delsol G. The interface of Hodgkin's disease and anaplastic large cell lymphoma. Cancer Surv 1997; 30: 87-105.
37. Jaffe ES, Harris NL, Diebold J, Müller-Hermelink HK. World Health Organization Classification of lymphomas: a work in progress. Ann Oncol 1998; 9 (Suppl 5): S25-30.
38. Falini B, Pileri S, Pizzolo G, et al. CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor super-family as a tool for diagnosis and immunotherapy. Blood 1995; 85(1): 1-14.
39. Delsol G, Al Saati T, Gatter KC, et al. Coexpression of epithelial membrane antigen (EMA), Ki-1, and interleukin-2 receptor by anaplastic large cell lymphomas. Diagnostic value in so-called malignant histiocytosis. Am J Pathol 1988; 130(1): 59-70.
40. Kutok JL, Aster JC. Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma. J Clin Oncol 2002; 20(17): 3691-3702.
41. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008; 8(1): 11-23.
42. Foss HD, Anagnostopoulos I, Araujo I, et al. Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules. Blood 1996; 88(10): 4005-4011.
43. Krenacs L, Wellmann A, Sorbara L, et al. Cytotoxic cell antigen expression in anaplastic large cell lymphomas of T- and null-cell type and Hodgkin's disease: evidence for distinct cellular origin. Blood 1997; 89(3): 980-989.
44. Liu QR, Chan PK. Formation of nucleophosmin/B23 oligomers requires both the amino- and the carboxyl-terminal domains of the protein. Eur J Biochem 1991; 200(3): 715-721.
45. Adachi Y, Copeland TD, Hatanaka M, Oroszlan S. Nucleolar targeting signal of Rex protein of human T-cell leukemia virus type I specifically binds to nucleolar shuttle protein B-23. J Biol Chem 1993; 268(19): 13930-13934.
46. Iwahara T, Fujimoto J, Wen D, et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 1997; 14(4): 439-449.
47. Morris SW, Naeve C, Mathew P, et al. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 1997; 14(18): 2175-2188.
48. Vernersson E, Khoo NK, Henriksson ML, Roos G, Palmer RH, Hallberg B. Characterization of the expression of the ALK receptor tyrosine kinase in mice. Gene Expr Patterns 2006; 6(5): 448-461.
49. Souttou B, Carvalho NB, Raulais D, Vigny M. Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway. J Biol Chem 2001; 276(12): 9526-9531.
50. Piccinini G, Bacchiocchi R, Serresi M, et al. A ligand-inducible epidermal growth factor receptor/anaplastic lymphoma kinase chimera promotes mitogenesis and transforming properties in 3T3 cells. J Biol Chem 2002; 277(25): 22231-22239.
51. Stoica GE, Kuo A, Aigner A, et al. Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem 2001; 276(20): 16772-16779.
52. Stoica GE, Kuo A, Powers C, et al. Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem 2002; 277(39): 35990-35998.
53. Perez-Pinera P, Zhang W, Chang Y, Vega JA, Deuel TF. Anaplastic lymphoma kinase is activated through the pleiotrophin/receptor protein-tyrosine phosphatase beta/zeta signaling pathway: an alternative mechanism of receptor tyrosine kinase activation. J Biol Chem 2007; 282(39): 28683-28690.
54. Fujimoto J, Shiota M, Iwahara T, et al. Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5). Proc Natl Acad Sci USA 1996; 93(9): 4181-4186.
55. Bischof D, Pulford K, Mason DY, Morris SW. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol 1997; 17(4): 2312-2325.
56. Bai RY, Dieter P, Peschel C, Morris SW, Duyster J. Nucleo-phosmin- anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol Cell Biol 1998; 18(12): 6951-6961.
57. Kuefer MU, Look AT, Pulford K, et al. Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood 1997; 90(8): 2901-2910.
58. Lange K, Uckert W, Blankenstein T, et al. Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice. Oncogene 2003; 22(4): 517-527.
59. Chiarle R, Gong JZ, Guasparri I, et al. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood 2003; 101(5): 1919-1927.
60. Jäger R, Hahne J, Jacob A, et al. Mice transgenic for NPM-ALK develop non-Hodgkin lymphomas. Anticancer Res 2005; 25(5): 3191-3196.
61. Hernández L, Beà S, Bellosillo B, et al. Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity. Am J Pathol 2002; 160(4): 1487-1494.
62. Colleoni GW, Bridge JA, Garicochea B, Liu J, Filippa DA, Ladanyi M, ATIC-ALK A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35). Am J Pathol 2000; 156(3): 781-789.
63. Ma Z, Cools J, Marynen P, et al. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. Blood 2000; 95(6): 2144-2149.
64. Touriol C, Greenland C, Lamant L, et al. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood 2000; 95(10): 3204-3207.
65. Gogusev J, Telvi L, Nezelof C. Molecular cytogenetic aberrations in CD30+ anaplastic large cell lymphoma cell lines. Cancer Genet Cytogenet 2002; 138(2): 95-101.
66. Mao X, Orchard G, Lillington DM, Russell-Jones R, Young BD, Whittaker S. Genetic alterations in primary cutaneous CD30+ anaplastic large cell lymphoma. Genes Chromosomes Cancer 2003; 37(2): 176-185.
67. Pulford K, Morris SW, Turturro F. Anaplastic lymphoma kinase proteins in growth control and cancer. J Cell Physiol 2004; 199(3): 330-358.
68. Bai RY, Ouyang T, Miething C, Morris SW, Peschel C, Duyster J. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 2000; 96(13): 4319-4327.
69. Zamo A, Chiarle R, Piva R, et al. Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death. Oncogene 2002; 21(7): 1038-1047.
70. Voena C, Conte C, Ambrogio C, et al. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration. Cancer Res 2007; 67(9): 4278-4286.
71. Chiarle R, Simmons WJ, Cai H, et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Med 2005; 11(6): 623-629.
72. Coluccia AM, Perego S, Cleris L, et al. Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo. Blood 2004; 103(7): 2787-2794.
73. Piva R, Pellegrino E, Mattioli M, et al. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. J Clin Invest 2006; 116(12): 3171-3182.
74. Tran H, Brunet A, Griffith EC, Greenberg ME. The many forks in FOXO's road. Sci STKE 2003; 2003(172): RE5.
75. Rassidakis GZ, Feretzaki M, Atwell C, et al. Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma. Blood 2005; 105(2): 827-829.
76. Slupianek A, Skorski T. NPM/ALK downregulates p27Kip1 in a PI-3K-dependent manner. Exp Hematol 2004; 32(12): 1265-1271.
77. Slupianek A, Nieborowska-Skorska M, Hoser G, et al. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res 2001; 61(5): 2194-2199.
78. Leventaki V, Drakos E, Medeiros LJ, et al. NPM-ALK oncogenic kinase promotes cell-cycle progression through activation of JNK/cJun signaling in anaplastic large-cell lymphoma. Blood 2007; 110(5): 1621-1630.
79. Lamant L, de Reyniès A, Duplantier MM, et al. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood 2007; 109(5): 2156-2164.
80. Thompson MA, Stumph J, Henrickson SE, et al. Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas. Hum Pathol 2005; 36(5): 494-504.
81. Salaverria I, Beà S, Lopez-Guillermo A, et al. Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas. Br J Haematol 2008; 140(5): 516-526.
82. Piccaluga PP, Agostinelli C, Califano A, et al. Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. Cancer Res 2007; 67(22): 10703-10710.